Telix Pharmaceuticals (ASX:TLX) has announced that the US FDA has accepted its Biologics License Application for its breakthrough investigational kidney cancer PET imaging agent TLX250-CDx (Zircaix, 89ZrDFO-girentuximab). …
US FDA accepts application for Telix's Zircaix and grants priority review
February 26, 2025 Australian Biotech
Latest Video
New Stories
-
AbbVie records a 13-year streak as 'A Great Place to Work'
July 29, 2026 - - Latest News -
Helping to build Australia’s life sciences future at Brisbane’s innovation junction
July 29, 2026 - - Latest News -
AFT Pharmaceuticals sees significant opportunity in a diverse R&D pipeline
July 28, 2026 - - Latest News -
New research shows chronic pain is widespread and undertreated in Australia
July 28, 2026 - - Latest News -
Long-COVID still reshaping life for medically vulnerable Australians
July 28, 2026 - - Latest News -
Australians with rare diseases still waiting too long for access to treatments
July 28, 2026 - - Latest News -
TGA approves GSK's six‑monthly treatment for severe eosinophilic asthma and nasal polyps
July 28, 2026 - - Latest News